If you have been reading about tesamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Alyssa Burrows said the band's distinctive sound "came from Staley's vocal style and his lyrics dealing with personal struggles and addiction." Staley's songs were often considered "dark", with themes such as drug abuse, depression, and suicide, while Cantrell's lyrics often dealt with personal relationships.
The 2012 Colombian peace process refers to the dialogue in Havana, Cuba between the Colombian government and the FARC-EP to find a political solution to the armed conflict. After almost four years of peace negotiations, the Colombian state and the FARC announced consenus on a 6-point plan towards peace and reconciliation. The government also began a process of assistance and reparation for victims of the conflict. Recently, U.P. supporters reconstituted the political party within the reconciliation process. Colombia's congress approved the revised peace accord. In February 2015, the Historical Commission on the Conflict and its Victims (Comisión Histórica del Conflicto Armado y sus Víctimas – CHCV) published a report entitled "Contribution to an Understanding of the Armed Conflict in Colombia." The document addresses the "multiple reasons for the conflict, the principle factors and circumstances that made it possible, and the most notable impacts on the population", and explains Colombia's armed conflict in terms of international law.
Because of its spread with humans worldwide, there has been some uncertainty about its exact original, native range, although it has been recognized as being likely in the subtropical parts of the Afro-Eurasia, thus with a preference for warmer climates, and recent authorities regards it as only native to Asia. As a synanthropic species, Pholcus phalangioides has largely had its modern geographic distribution determined by the spread of humans around the world. Today, these spiders can be found in most of the temperate countries of every continent in the world. P. phalangioides are not suited for survival in cold environments, which is why they prefer the warmth of the indoors when in these regions, specifically inside human dwellings. These spiders have a particular affinity for dimly lit, dark areas that are quiet and calm. They are commonly found in the corners of buildings and people's homes as well as in attics. Populations of Pholcus phalangioides living outdoors can be found in caves and in between rock crevices.
== History == In 1999 it became a wholly owned subsidiary of the publicly held Cracker Barrel. On December 6, 2006, Logan's Roadhouse was sold to affiliates of Bruckmann, Rosser, Sherrill & Co., Canyon Capital Advisors LLC, and Black Canyon Capital LLC for $486 million. In 2010, private equity firm Kelso & Company acquired the company. On February 20, 2013, Mike Andres, a former McDonald's vice-president and former chief executive officer of Boston Market, replaced Tom Vogel as chief executive officer. On January 12, 2017, Hazem Ouf, former chief executive officer of American Blue Ribbon Holdings, was named president and chief executive officer. On August 8, 2016, Logan's Roadhouse filed for bankruptcy and announced plans to close eighteen of its 256 locations that are under-performing. The chain was reported to be struggling with heavy debt and falling sales. Locations closing in late September 2016, include, in Florida, two each in Kissimmee and Orlando, and one each in Mary Esther, Tampa, and Tallahassee; one in each of those cities: Macon, Georgia; Houston, Texas; Lafayette, Louisiana and Waynesboro, Virginia. On December 1, 2016, Logan's Roadhouse formally exited bankruptcy with a debt load reduced from about $400 million to $100 million. On November 1, 2018, Logan's Roadhouse announced that it was acquired by CraftWorks Restaurants & Breweries. On March 3, 2020, Craftworks filed for Chapter 11 Bankruptcy protection. On March 19, 2020, all open Logan's locations were temporarily closed amid the COVID-19 pandemic.
Sources: en.wikipedia.org
Maturity-onset diabetes of the young (MODY) is a rare autosomal dominant inherited form of diabetes, due to one of several single-gene mutations causing defects in insulin production. It is significantly less common than the three main types, constituting 1–2% of all cases. The name of this disease refers to early hypotheses as to its nature. Being due to a defective gene, this disease varies in age at presentation and in severity according to the specific gene defect; thus, there are at least 14 subtypes of MODY. People with MODY often can control it without using insulin.
=== REM sleep behavior disorder === Melatonin is a safer alternative than clonazepam in the treatment of REM sleep behavior disorder – a condition associated with the synucleinopathies like Parkinson's disease and dementia with Lewy bodies. However, clonazepam may be more effective. In any case, the quality of evidence for both treatments is very low and it is unclear whether either is definitely effective.
In either case, a mixture of unbound ligands, proteins, ligand-protein complexes is passed through a column of porous beads. Ligand-protein complexes are excluded from entering the beads and exit the column quickly, while unbound ligands must travel through the beads and are retained by the column for a longer time. Ligands that elute from the column early on are therefore inferred to be bound to a protein. The automated ligand identification system (ALIS), developed by Schering-Plough, uses a combined HPLC-based SEC to liquid chromatography-mass spectrometry (LC-MS) system that separates ligand-protein complexes from unbound ligands using SEC and diverts the complex toward an LC-MS system for on-line analysis of bound ligands. Novartis' SpeedScreen uses SEC in 96-well spin column format, also known as gel filtration chromatography, which allows for simultaneous removal of unbound ligands from up to 96 samples. Samples are also passed through porous beads, but centrifugation is used to move the sample through the column. SpeedScreen is not coupled to an LC-MS system and requires further processing prior to final analysis. In this case, ligands must be freed from their targets and analyzed separately.
===== Polyolefins ===== To aid with the catalyst research for polyolefins, Symyx Technologies Inc. used automated synthesis to create a library of palladium and nickel catalysts, which were screened for ethylene polymerization. This process found that the largest polyethylene polymers were created by the complexes with the highest steric hindrance for the ortho-positions of the aryl rings, while electronic factors did not influence yield or molecular weight. In addition, Tuchbreiter and Mülhaupt used automated synthesis to demonstrate the improvements of minireactors for the polymerization of olefins, with quality improving as compared to utilizing simple arrays.
=== Pharmacodynamics === Paroxetine is the most potent and one of the most specific selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRIs). It also binds to the allosteric site of the serotonin transporter, similarly to escitalopram, though less potently so. Paroxetine also inhibits the reuptake of norepinephrine to a lesser extent (<50 nmol/L). Based on evidence from four weeks of administration in rats, the equivalent of 20 mg paroxetine taken once daily occupies approximately 88% of serotonin transporters in the prefrontal cortex. Paroxetine is a phenylpiperidine and might have some affinity for opioid receptors.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.